​

Parabilis Medicines Stock (NASDAQ:PBLS)

RevenueOwnershipFinancialsChart
Parabilis Medicines by TradingView

Previous Close

$27.69

52W Range

$20.00 - $42.49

50D Avg

$31.11

200D Avg

$31.95

Market Cap

$3.47B

Avg Vol (3M)

$945.43K

Beta

5.03

Div Yield

-

PBLS Company Profile

Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

145

IPO Date

Jun 10, 2026

Website

PBLS Performance

PBLS Financial Summary

Dec 25Dec 24
Revenue--
Operating Income$-152.08M$-126.13M
Net Income$-145.89M$-117.91M
EBITDA$-141.87M$-114.33M
Basic EPS$-92.40$-83.48
Diluted EPS$-92.40$-83.48

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
ZYMEZymeworks Inc.
CBIOCrescent Biopharma, Inc.
GLUEMonte Rosa Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
TNGXTango Therapeutics, Inc.
IMNMImmunome, Inc.
MGNXMacroGenics, Inc.
FHTXFoghorn Therapeutics Inc.
CGEMCullinan Therapeutics, Inc.